| payload |
{"created_at":"2026-04-08T02:28:02.401 {"created_at":"2026-04-08T02:28:02.401723+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:56dca9c0992eb439","evidence_event_ids":["evt_da306f3a470d"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/pharma-dividend-has-been-raised-every-single-year-over-decade","as_of":"2026-04-08T02:28:02.401723+00:00","canonical_url":"https://www.fool.com/investing/2026/04/07/this-pharma-dividend-has-been-raised-every-single/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/pharma-dividend-has-been-raised-every-single-year-over-decade","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_7307f9860a240988","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/07/this-pharma-dividend-has-been-raised-every-single/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-08T03:51:26.274981+00:00","extraction_method":"heuristic","fetched_description":"Key PointsAbbVie has successfully navigated through a major patent cliff, enabling it to sustain a dividend growth streak for more than a decade.","fetched_title":"This Pharma Dividend Has Been Raised Every Single Year for Over a Decade | Nasdaq","final_url":"https://www.nasdaq.com/articles/pharma-dividend-has-been-raised-every-single-year-over-decade","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/pharma-dividend-has-been-raised-every-single-year-over-decade","source_event_id":"evt_da306f3a470d","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"031d34da1cba2da2","kind":"unusual_volume","published_at":"2026-04-08T01:50:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["April 07, 2026","2013","Late last year","2025","2030","2026","2027"],"entities":[{"asset_class":"equity","name":"AbbVie","relevance":"high","symbol":"ABBV","type":"company"},{"asset_class":"equity","name":"Abbott Laboratories","relevance":"medium","symbol":"","type":"company"},{"asset_class":"other","name":"Humira","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"Skyrizi","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"Rinvoq","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"Vraylar","relevance":"medium","symbol":"","type":"drug"},{"asset_class":"other","name":"Botox Therapeutic","relevance":"medium","symbol":"","type":"drug"},{"asset_class":"other","name":"Ubrelvy","relevance":"medium","symbol":"","type":"drug"}],"event_type":"earnings","information_gaps":["This signal type is 'discovery_unusual_volume_delta', but the provided text contains no volume ratio, baseline volume, or confirmation of unusual trading volume.","No explicit statement links the dividend news to a specific trading-volume spike or whether any volume change is unexplained.","The article does not provide a specific catalyst date/time for the dividend increase beyond 'late last year'."],"key_facts":["AbbVie was spun off from Abbott Laboratories in 2013.","The article states AbbVie has raised its quarterly dividend each year since becoming independent.","The article says AbbVie faced a major headwind from losing major patent exclusivity for Humira.","The article attributes dividend growth resilience to launches of Skyrizi and Rinvoq.","The article states Skyrizi and Rinvoq generated $31 billion in revenue in 2025 and are forecast to reach around $50 billion by 2030.","The article states AbbVie announced a 5.5% increase to its quarterly dividend, raising it to $1.73 per share (or $6.92 annually).","The article states the forward dividend yield is around 3.2%.","The article states forecasts call for earnings to rise by around 45.4% in 2026 and 10.8% in 2027.","The article states the stock sells for around 17 times forward earnings.","The article frames the likely catalyst as continued growth in Skyrizi and Rinvoq (and additional growth from the neuroscience portfolio) supporting future earnings and dividend increases."],"numeric_claims":[{"label":"Dividend increase","value":"5.5% (quarterly)"},{"label":"Quarterly dividend","value":"$1.73 per share"},{"label":"Annual dividend","value":"$6.92 per share"},{"label":"Forward dividend yield","value":"~3.2%"},{"label":"Skyrizi + Rinvoq revenue (2025)","value":"$31 billion"},{"label":"Skyrizi + Rinvoq revenue (2030 forecast)","value":"~$50 billion"},{"label":"Earnings growth forecast (2026)","value":"~45.4%"},{"label":"Earnings growth forecast (2027)","value":"~10.8%"},{"label":"Forward earnings multiple","value":"~17x"}],"primary_claim":"AbbVie has raised its quarterly dividend each year since becoming an independent, publicly traded company in 2013, and it recently increased the quarterly dividend by 5.5% to $1.73 per share.","relevance_score":0.35,"sentiment":"positive","source_quality":"high","summary":"The article highlights AbbVie (ABBV) as a dividend growth stock, stating it has raised its quarterly dividend every year since becoming an independent company in 2013 and recently increased it by 5.5%. It attributes the streak to offsetting Humira patent-cliff headwinds with growth from Skyrizi and Rinvoq.","topics":["dividend growth","patent cliff","Humira","Skyrizi","Rinvoq","forecasted revenue","forecasted earnings","valuation","buy and hold"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsAbbVie has successfully navigated through a major patent cliff, enabling it to sustain a dividend growth streak for more than a decade.","tickers":[],"title":"This Pharma Dividend Has Been Raised Every Single Year for Over a Decade","url":"https://www.fool.com/investing/2026/04/07/this-pharma-dividend-has-been-raised-every-single/"}}... |